Altre lingue Endo International plc

Azioni

ENDPQ

IE00BJ3V9050

Mercato chiuso - OTC Markets Altri mercati azionari 17:04:08 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,0006 ^USD	0,00%		-14,29%	+20,00%

19/03	Il produttore di farmaci Endo riceve l'approvazione del tribunale statunitense per la ristrutturazione fallimentare	RE
06/03	Endo International plc riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Endo International plc - Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution	23/04
Endo, Inc. Announces Proposed New Senior Secured Credit Facilities	02/04
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS	27/03
Fourth Amended Joint Reorganization Plan Approved for Endo International plc	22/03
Health Care Down on Rate Bias -- Health Care Roundup	20/03
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET	20/03
Drugmaker Endo receives US court approval for bankruptcy restructuring	19/03
Drugmaker Endo receives US court approval for bankruptcy restructuring, Bloomberg News reports	19/03
Fourth Amended Joint Reorganization Plan Filed by Endo International plc	18/03
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution	12/03
North American Morning Briefing : Stock Futures -2-	11/03
Health Care Flat After Trial Setbacks -- Health Care Roundup	08/03
Endo International plc Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Endo International plc Reports Property, Plant and Equipment Impairment Charges for the Three Months Ended December 31, 2023	06/03
Endo International plc Provides Earnings Guidance for the Year 2024	06/03
Endo International plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS	06/03
Endo va payer 2 milliards de dollars à cause d'un traitement opiacé	29/02
Drugmaker Endo reaches $465 mln bankruptcy settlement with US	29/02
Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER	29/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Endo International plc

Azioni

ENDPQ

IE00BJ3V9050

Altre lingue

Filtri